Lapatinib as second-line treatment after the double block pertuzumab-trastuzumab: a case report
We report the case of a young, 36-year-old patient diagnosed with multifocal breast carcinoma, undergoing neoadjuvant chemotherapy, surgery and adjuvant treatment. The patient presented an early recovery of liver disease after only 7 months of free interval. Histological reevaluation after liver bio...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2018-10-01
|
| Series: | AboutOpen |
| Subjects: | |
| Online Access: | https://journals.aboutscience.eu/index.php/aboutopen/article/view/131 |
| _version_ | 1818789225122758656 |
|---|---|
| author | Valentina Magri Simone Scagnoli Gabriele Piesco Giulia Pomati |
| author_facet | Valentina Magri Simone Scagnoli Gabriele Piesco Giulia Pomati |
| author_sort | Valentina Magri |
| collection | DOAJ |
| description | We report the case of a young, 36-year-old patient diagnosed with multifocal breast carcinoma, undergoing neoadjuvant chemotherapy, surgery and adjuvant treatment. The patient presented an early recovery of liver disease after only 7 months of free interval. Histological reevaluation after liver biopsy revealed a HER2-positive disease, for which it was treated with first line chemotherapy including double anti-HER2 block. After 3 cycles the disease progressed at liver and encephalic level. It was therefore decided to treat brain localizations with whole-brain radiotherapy and to start a second line with capecitabine associated with lapatinib. This chemo-radiotherapy approach allowed to control the disease for 8 months. Following further progression (lymph node and bone), a third line was chosen with trastuzumab emtansine (TDM1). The encephalic disease remained stable for another 8 months, when due to visceral progression and worsening of clinical picture, TDM1 was interrupted and supportive therapies were started (Oncology).
. |
| first_indexed | 2024-12-18T14:36:10Z |
| format | Article |
| id | doaj.art-dedb2c2fc53e4a69833709614becf882 |
| institution | Directory Open Access Journal |
| issn | 2465-2628 |
| language | English |
| last_indexed | 2024-12-18T14:36:10Z |
| publishDate | 2018-10-01 |
| publisher | AboutScience Srl |
| record_format | Article |
| series | AboutOpen |
| spelling | doaj.art-dedb2c2fc53e4a69833709614becf8822022-12-21T21:04:30ZengAboutScience SrlAboutOpen2465-26282018-10-014110.19156/abtpn.2018.0071Lapatinib as second-line treatment after the double block pertuzumab-trastuzumab: a case reportValentina Magri0Simone Scagnoli1Gabriele Piesco2Giulia Pomati3Oncologia, Policlinico Umberto I, Roma - ItalyOncologia, Policlinico Umberto I, Roma - ItalyOncologia, Policlinico Umberto I, Roma - ItalyOncologia, Policlinico Umberto I, Roma - ItalyWe report the case of a young, 36-year-old patient diagnosed with multifocal breast carcinoma, undergoing neoadjuvant chemotherapy, surgery and adjuvant treatment. The patient presented an early recovery of liver disease after only 7 months of free interval. Histological reevaluation after liver biopsy revealed a HER2-positive disease, for which it was treated with first line chemotherapy including double anti-HER2 block. After 3 cycles the disease progressed at liver and encephalic level. It was therefore decided to treat brain localizations with whole-brain radiotherapy and to start a second line with capecitabine associated with lapatinib. This chemo-radiotherapy approach allowed to control the disease for 8 months. Following further progression (lymph node and bone), a third line was chosen with trastuzumab emtansine (TDM1). The encephalic disease remained stable for another 8 months, when due to visceral progression and worsening of clinical picture, TDM1 was interrupted and supportive therapies were started (Oncology). .https://journals.aboutscience.eu/index.php/aboutopen/article/view/131LapatinibMultifocal breast cancerHepatic metastasesBrain metastases |
| spellingShingle | Valentina Magri Simone Scagnoli Gabriele Piesco Giulia Pomati Lapatinib as second-line treatment after the double block pertuzumab-trastuzumab: a case report AboutOpen Lapatinib Multifocal breast cancer Hepatic metastases Brain metastases |
| title | Lapatinib as second-line treatment after the double block pertuzumab-trastuzumab: a case report |
| title_full | Lapatinib as second-line treatment after the double block pertuzumab-trastuzumab: a case report |
| title_fullStr | Lapatinib as second-line treatment after the double block pertuzumab-trastuzumab: a case report |
| title_full_unstemmed | Lapatinib as second-line treatment after the double block pertuzumab-trastuzumab: a case report |
| title_short | Lapatinib as second-line treatment after the double block pertuzumab-trastuzumab: a case report |
| title_sort | lapatinib as second line treatment after the double block pertuzumab trastuzumab a case report |
| topic | Lapatinib Multifocal breast cancer Hepatic metastases Brain metastases |
| url | https://journals.aboutscience.eu/index.php/aboutopen/article/view/131 |
| work_keys_str_mv | AT valentinamagri lapatinibassecondlinetreatmentafterthedoubleblockpertuzumabtrastuzumabacasereport AT simonescagnoli lapatinibassecondlinetreatmentafterthedoubleblockpertuzumabtrastuzumabacasereport AT gabrielepiesco lapatinibassecondlinetreatmentafterthedoubleblockpertuzumabtrastuzumabacasereport AT giuliapomati lapatinibassecondlinetreatmentafterthedoubleblockpertuzumabtrastuzumabacasereport |